
METHYLPREDNISOLONE - methylprednisolone tablet Lupin Pharmaceuticals, Inc.

Methylprednisolone Tablets USP

DESCRIPTION

Methylprednisolone tablets USP contain methylprednisolone which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Methylprednisolone occurs as a white to practically white, odorless, crystalline powder. It is sparingly soluble in alcohol, in dioxane, and in methanol, slightly soluble in acetone, and in chloroform, and very slightly soluble in ether. It is practically insoluble in water.

The chemical name for methylprednisolone is pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-,(6α , 11 β)- and the molecular weight is 374.5. The structural formula is represented below:



Each methylprednisolone tablets USP for oral administration contains 2 mg, 4 mg, 8 mg, 16 mg, or 32 mg of methylprednisolone. In addition, each tablet contains the inactive ingredients colloidal silicon dioxide, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium starch glycolate.

ACTIONS

Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have saltretaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.

Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

INDICATIONS AND USAGE

Methylprednisolone tablets are indicated in the following conditions:

1. Endocrine Disorders

Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).

Congenital adrenal hyperplasia

Nonsuppurative thyroiditis

Hypercalcemia associated with cancer

2. Rheumatic Disorders

As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:

Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)

Ankylosing spondylitis

Acute and subacute bursitis

Synovitis of osteoarthritis

Acute nonspecific tenosynovitis

Post-traumatic osteoarthritis

Psoriatic arthritis

Epicondylitis

Acute gouty arthritis

3. Collagen Diseases

During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis

4. Dermatologic Diseases

Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis

5. Allergic States

Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:

Seasonal or perennial allergic rhinitis

Drug hypersensitivity reactions

Serum sickness

Contact dermatitis

Bronchial asthma

Atopic dermatitis

6. Ophthalmic Diseases

Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:

Allergic corneal marginal ulcers

Herpes zoster ophthalmicus

Anterior segment inflammation

Diffuse posterior uveitis and choroiditis

Sympathetic ophthalmia

Keratitis

Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis

7. Respiratory Diseases

Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means

Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy

Aspiration pneumonitis

8. Hematologic Disorders

Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia

9. Neoplastic Diseases

For palliative management of:

Leukemias and lymphomas in adults

Acute leukemia of childhood

10. Edematous States

To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.

11. Gastrointestinal Diseases

To tide the patient over a critical period of the disease in:

Ulcerative colitis

Regional enteritis

12. Nervous System

Acute exacerbations of multiple sclerosis

13. Miscellaneous

Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.

Trichinosis with neurologic or myocardial involvement.

CONTRAINDICATIONS

Systemic fungal infections and known hypersensitivity to components.

WARNINGS

In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.

Corticosteroids may mask some signs of infection, and new infections may appear during their use. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic infections, in any location of the body, may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function.¹

These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases.² There may be decreased resistance and inability to localize infection when corticosteroids are used.

Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.

Usage in pregnancy

Since adequate human reproduction studies have not been done with corticosteroids, the use of these drugs in pregnancy, nursing mothers or women of child-bearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy, should be carefully observed for signs of hypoadrenalism. pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.

Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered to patients receiving immunosuppressive doses of corticosteroids; however, the response to such vaccines may be diminished. Indicated immunization procedures may be undertaken in patients receiving nonimmunosuppressive doses of corticosteroids.

The use of methylprednisolone tablets in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.

If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.

Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In such children or adults who have not had these diseases particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed, to chicken pox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chicken pox develops, treatment with antiviral agents may be considered. Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.

PRECAUTIONS

General Precautions

Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after

discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.

There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis.

Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.

The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.

Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.

Caution is required in patients with systemic sclerosis because an increased incidence of scleroderma renal crisis has been observed with corticosteroids, including methylprednisolone.

Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis.

Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.

Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy. Discontinuation of corticosteroids may result in clinical remission.

Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See DOSAGE AND ADMINISTRATION.)

Since complications of treatment with glucocorticoids are dependent on the size of the

dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.

DRUG INTERACTIONS

The pharmacokinetic interactions listed below are potentially clinically important. Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; therefore, it is possible that adverse events associated with the individual use of either drug may be more apt to occur. Convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of methylprednisolone and may require increases in methylprednisolone dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. Therefore, the dose of methylprednisolone should be titrated to avoid steroid toxicity.

Methylprednisolone may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.

The effect of methylprednisolone on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.

Information for the Patient

Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.

ADVERSE REACTIONS

Fluid and Electrolyte Disturbances

- Sodium retention
- Congestive heart failure in susceptible patients
- Hypertension
- Fluid retention
- Potassium loss
- Hypokalemic alkalosis

Musculoskeletal

- Muscle weakness
- Loss of muscle mass
- Steroid myopathy
- Osteoporosis
- Tendon rupture, particularly of the Achilles tendon
- Vertebral compression fractures
- Aseptic necrosis of femoral and humeral heads
- Pathologic fracture of long bones

Gastrointestinal

- Peptic ulcer with possible perforation and hemorrhage
- Pancreatitis
- Abdominal distention
- Ulcerative esophagitis

Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT), and alkaline phosphatase have been observed following corticosteroid treatment. These changes are usually small, not associated with any clinical syndrome and are reversible upon discontinuation.

Dermatologic

- Impaired wound healing
- Petechiae and ecchymoses
- May suppress reactions to skin tests
- Thin fragile skin
- Facial erythema
- Increased sweating

Neurological

- Increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment
- Convulsions
- Vertigo
- Headache

Endocrine

- Development of Cushingoid state
- Suppression of growth in children
- Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness
- Menstrual irregularities
- Decreased carbohydrate tolerance
- Manifestations of latent diabetes mellitus
- Increased requirements of insulin or oral hypoglycemic agents in diabetics

Ophthalmic

- Posterior subcapsular cataracts
- Increased intraocular pressure
- Glaucoma
- Exophthalmos

Metabolic

• Negative nitrogen balance due to protein catabolism

The following additional reactions have been reported following oral as well as parenteral therapy: Urticaria and other allergic, anaphylactic or hypersensitivity reactions.

DOSAGE AND ADMINISTRATION

The initial dosage of methylprednisolone tablets may vary from 4 mg to 48 mg of methylprednisolone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, methylprednisolone tablets should be discontinued and the patient transferred to other appropriate therapy.

IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of methylprednisolone tablets for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.

Multiple Sclerosis

In treatment of acute exacerbations of multiple sclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day for 1 month have been shown to be effective (4 mg of methylprednisolone is equivalent to 5 mg of prednisolone).

Alternate day therapy is a corticosteroid dosing regimen in which twice the usual daily dose of corticoid is administered every other morning. The purpose of this mode of therapy is to provide the patient requiring long-term pharmacologic dose treatment with the beneficial effects of corticoids while minimizing certain undesirable effects, including pituitary-adrenal suppression, the Cushingoid state, corticoid withdrawal symptoms, and growth suppression in children.

The rationale for this treatment schedule is based on two major premises: (a) the antiinflammatory or therapeutic effect of corticoids persists longer than their physical presence and metabolic effects and (b) administration of the corticosteroid every other morning allows for reestablishment of more nearly normal hypothalamic-pituitaryadrenal (HPA) activity on the off-steroid day.

A brief review of the HPA physiology may be helpful in understanding this rationale. Acting primarily through the hypothalamus a fall in free cortisol stimulates the pituitary gland to produce increasing amounts of corticotropin (ACTH) while a rise in free cortisol inhibits ACTH secretion. Normally the HPA system is characterized by diurnal (circadian) rhythm. Serum levels of ACTH rise from a low point about 10 pm to a peak level about 6 am. Increasing levels of ACTH stimulate adrenal cortical activity resulting in a rise in plasma cortisol with maximal levels occurring between 2 am and 8 am. This rise in cortisol dampens ACTH production and in turn adrenal cortical activity. There is a gradual fall in plasma corticoids during the day with lowest levels occurring about midnight.

The diurnal rhythm of the HPA axis is lost in Cushing's disease, a syndrome of adrenal cortical hyperfunction characterized by obesity with centripetal fat distribution, thinning of the skin with easy bruisability, muscle wasting with weakness, hypertension, latent diabetes, osteoporosis, electrolyte imbalance, etc. The same clinical findings of hyperadrenocorticism may be noted during long-term pharmacologic dose corticoid therapy administered in conventional daily divided doses. It would appear, then, that a disturbance in the diurnal cycle with maintenance of elevated corticoid values during the night may play a significant role in the development of undesirable corticoid effects. Escape from these constantly elevated plasma levels for even short periods of time may be instrumental in protecting against undesirable pharmacologic effects.

During conventional pharmacologic dose corticosteroid therapy, ACTH production is inhibited with subsequent suppression of cortisol production by the adrenal cortex. Recovery time for normal HPA activity is variable depending upon the dose and duration of treatment. During this time the patient is vulnerable to any stressful situation. Although it has been shown that there is considerably less adrenal suppression following a single morning dose of prednisolone (10 mg) as opposed to a quarter of that dose administered every six hours, there is evidence that some suppressive effect on adrenal activity may be carried over into the following day when pharmacologic doses are used. Further, it has been shown that a single dose of certain corticosteroids will produce adrenal cortical suppression for two or more days. Other corticoids, including methylprednisolone, hydrocortisone, prednisone, and prednisolone, are considered to be short acting (producing adrenal cortical suppression for $1\frac{1}{4}$ to $1\frac{1}{2}$ days following a single dose) and thus are recommended for alternate day therapy.

The following should be kept in mind when considering alternate day therapy:

1) Basic principles and indications for corticosteroid therapy should apply. The benefits of alternate day therapy should not encourage the indiscriminate use of steroids.

2) Alternate day therapy is a therapeutic technique primarily designed for patients in whom long-term pharmacologic corticoid therapy is anticipated.

3) In less severe disease processes in which corticoid therapy is indicated, it may be possible to initiate treatment with alternate day therapy. More severe disease states usually will require daily divided high dose therapy for initial control of the disease process. The initial suppressive dose level should be continued until satisfactory clinical response is obtained, usually four to ten days in the case of many allergic and collagen diseases. It is important to keep the period of initial suppressive dose as brief as possible particularly when subsequent use of alternate day therapy is intended.

4) Once control has been established, two courses are available: (a) change to alternate day therapy and then gradually reduce the amount of corticoid given every other day **or** (b) following control of the disease process reduce the daily dose of corticoid to the lowest effective level as rapidly as possible and then change over to an alternate day schedule. Theoretically, course (a) may be preferable.

5) Because of the advantages of alternate day therapy, it may be desirable to try patients on this form of therapy who have been on daily corticoids for long periods of time (eg, patients with rheumatoid arthritis). Since these patients may already have a suppressed HPA axis, establishing them on alternate day therapy may be difficult and not always successful. However, it is recommended that regular attempts be made to change them over. It may be helpful to triple or even quadruple the daily maintenance dose and administer this every other day rather than just doubling the daily dose if difficulty is encountered. Once the patient is again controlled, an attempt should be made to reduce this dose to a minimum.

6) As indicated above, certain corticosteroids, because of their prolonged suppressive effect on adrenal activity, are not recommended for alternate day therapy (eg, dexamethasone and betamethasone).

7) The maximal activity of the adrenal cortex is between 2 am and 8 am, and it is minimal between 4 pm and midnight. Exogenous corticosteroids suppress adrenocortical activity the least, when given at the time of maximal activity (am).

8) In using alternate day therapy it is important, as in all therapeutic situations to individualize and tailor the therapy to each patient. Complete control of symptoms will not be possible in all patients. An explanation of the benefits of alternate day therapy will help the patient to understand and tolerate the possible flare-up in symptoms which may occur in the latter part of the off-steroid day. Other symptomatic therapy may be added or increased at this time if needed.

9) In the event of an acute flare-up of the disease process, it may be necessary to return to a full suppressive daily divided corticoid dose for control. Once control is again

established alternate day therapy may be reinstituted.

10) Although many of the undesirable features of corticosteroid therapy can be minimized by alternate day therapy, as in any therapeutic situation, the physician must carefully weigh the benefit-risk ratio for each patient in whom corticoid therapy is being considered.

HOW SUPPLIED

Methylprednisolone Tablets USP are available in the following strengths and package sizes:

2 mg (White to off white, elliptical shaped tablets debossed with 'L10' on one side and crossed score line on the other side)

Bottles of 100 Tablets NDC 688180-685-01

4 mg (White to off white, elliptical shaped tablets debossed with 'L11' on one side and crossed score line on the other side)

Bottles of 100 Tablets NDC 688180-686-01

Unit of Use blister package of 21

(21 tablets blister in one carton) NDC 688180-686-11

8 mg (White to off white, elliptical shaped tablets debossed with 'L12' on one side and single score line on the other side)

Bottles of 25 Tablets

NDC 688180-687-55

16 mg (White to off white, elliptical shaped tablets debossed with 'L13' on one side and crossed score line on the other side)

Bottles of 50 Tablets

NDC 688180-688-08

32 mg (White to off white, elliptical shaped tablets debossed with 'L14' on one side and single score line on the other side.)

Bottles of 25 Tablets

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

REFERENCES

1. Fekety R. Infections associated with corticosteroids and immunosuppressive therapy. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious Diseases. Philadelphia: WBSaunders Company 1992:1050–1.

2. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticoids. Rev Infect Dis 1989:11(6):954–63.

Rx only

Manufactured for:

Lupin Pharmaceuticals, Inc.

Baltimore, Maryland 21202

United States

Manufactured by:

Lupin Limited

Nagpur 441 108

INDIA

Revised August 2018

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 68180-685-01 Methylprednisolone Tablets USP 2 mg Rx only Bottle of 100 Tablets

| | NDC 6818 | 0-685-01 | Usual Dosage: See acc prescribing information Storage: Store at 25°C | | 5 | |
|---|------------------------------------|--------------------|---|---------------------------------------|----------|------------------------------|
| | MethylPl Tablets U | REDNISolone JSP | permitted to 15° to 30° [See USP Controlled Re PROTECT FROM LIGH | Č (59° to 86°F). oom Temperature]. | | Unvarnish Area 15 x 30 mm |
| | 2 mg | | Dispense in tight (USP) child-resistant containe Keep patient under clos of a physician. | rs. | 0 16 8 5 | Unvarni 15 x 30 |
| | Each tablet cont methylpredniso | | Manufactured for: Lupin Pharmaceutical Baltimore, Maryland 21 | | 6818 | |
| _ | R x only | | Manufactured by: Lupin Limited Nagpur - 441 108, IND | A. | ZM | |
| | LUPIN | 100 Tablets | Code No.: | XXXXXX | | LOT NO. EXP. |

NDC 68180-686-01

| Mathaul | no vr o ol v | | T | | |
|---------|--------------|-------|------|--------|-----|
| Methyl | prea | nisoi | onei | ablets | USP |

4 mg

Rx only

Bottle of 100 Tablets


| NDC 68180-686-01 | Usual Dosage: See accompanying prescribing information. Storage: Store at 25°C (77°F); excursions | 6 | |
|--|--|----------|------------------------------|
| MethylPREDNISolone Tablets USP | permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]. PROTECT FROM LIGHT. | | Unvarnish Area 15 x 30 mm |
| 4 mg | Dispense in tight (USP), child-resistant containers. Keep patient under close observation of a physician. | 0 16 8 6 | Unvarni 15 x 30 |
| Each tablet contains 4 mg of methylprednisolone USP. | Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, United States. | 6818 | |
| Rx only | Manufactured by: Lupin Limited Nagpur - 441 108, INDIA. | ZM | LOT NO. |
| LUPIN 100 Tablets | Code No.: XXXXXX | | LOT EXP. |

NDC 68180-686-11

Methylprednisolone Tablets USP

4 mg

Rx only



NDC 68180-686-11

Methylprednisolone Tablets USP

4 mg

Rx only

Unit of Use blister package of 21 (21 tablets blister in one carton)

| _ | | |
|---|--|-------|
| | NDC 68180-686-11 MethylPREDNISolone Tablets USP | |
| | 4 mg per tablet Each tablet contains 4 mg of methylprednisolone USP. PACKAGE NOT CHILD-RESISTANT # Rx only | |
| - | LUPIN 21 Tablets Usual Dosage: See accompanying prescribing information. Keep patient under close observation of a physician. Storage: Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Keep Dut of Reach of Children. | LOTI |
| Moc saledee-11 MethylPREDNISolone Tablets USP Amg per tables Kante Luppen 21 Tables | NDC 68180-686-11 MethylPREDNISolone Tablets USP A mg per tablet Each tablet contains 4 mg of methylprednisolone USP. Unit of Use PACKAGE NOT CHILD-RESISTANT Rx only UPIN 21 Tablets | 64 mm |
| lets | Manufactured for: Manufactured by: Lupin Pharmaceuticals, Inc. Lupin Limited Bal timore, Maryland 21202 United States Nagpur – 441 108 INDIA Code No.: XXXXXX | 21 mm |

NDC 68180-687-55

Methylprednisolone Tablets USP

8 mg

Rx only

Bottle of 25 Tablets

| | NDC 68180 | -687-55 | Usual Dosage: See according prescribing information. Storage: Store at 25°C | | 6 | |
|---|--|-----------------|--|--------------------------------------|------|------------------------------|
| | MethylPRE Tablets US | EDNISolone P | permitted to 15° to 30°C [See USP Controlled Ro PROTECT FROM LIGHT | C (59° to 86°F). om Temperature]. | 5 5 | Unvarnish Area 15 x 30 mm |
| | 8 mg | | Dispense in tight (USP), child-resistant container Keep patient under close of a physician. | ſS. | | Unvarni 15 x 30 |
| | Each tablet contair methylprednisolon | • | Manufactured for: Lupin Pharmaceuticals Baltimore, Maryland 212 | | 6818 | |
| ± | Rx only | | Manufactured by: Lupin Limited Nagpur - 441 108, INDI. | Α. | ZM | |
| | LUPIN | 25 Tablets | Code No.: | XXXXXX | | LOT NO. EXP. |

NDC 68180-688-08

| Moth | Inroc | Inico | lono ⁻ | Tablets | |
|-------|---------|-------|-------------------|---------|-----|
| Methy | yipi ec | 11150 | IONE | Ianierz | USF |

16 mg

Rx only

Bottle of 50 Tablets


| N | IDC 68180-688 | -08 | Usual Dosage: See acc prescribing information Storage: Store at 25°C | l. | ons | 2 | | |
|-----|--|-----------|---|----------------------------------|-------|----------|---------|------------------------------|
| | MethylPREDNI Fablets USP | Solone | permitted to 15° to 30° [See USP Controlled Ro PROTECT FROM LIGHT | Ć (59° to 86°F) oom Temperatu | | 80 | | Unvarnish Area 15 x 30 mm |
| | 16 mg | | Dispense in tight (USP) child-resistant containe Keep patient under clos of a physician. | rs. | | 0 16 8 8 | | Unvarn 15 x 30 |
| | ach tablet contains 16 m ethylprednisolone USP. | | Manufactured for: Lupin Pharmaceuticals Baltimore, Maryland 21 | | ates. | 6818 | | |
| R | x only | | Manufactured by: Lupin Limited Nagpur - 441 108, IND | IA. | | ZM | LOT NO. | |
| *** | UPIN 5 | 0 Tablets | Code No.: | > | XXXXX | | LOT | EXP. |

NDC 68180-689-55

Methylprednisolone Tablets USP

32 mg

Rx only



| METHYLPREDNISOL | .ONE | | | | | |
|--|-----------------|-----------------------------|-----------|--------------------|---------|----------|
| methylprednisolone tablet | | | | | | |
| | | | | | | |
| Product Information | | | | | | |
| Product Type | HUMAN PRES | CRIPTION DRUG | ltem Code | (Source) | NDC:6 | 8180-685 |
| Route of Administration | ORAL | | | | | |
| | | | | | | |
| | | | | | | |
| Active Ingredient/Active | e Moiety | | | | | |
| Ing | gredient Nan | ne | | Basis of St | rength | Strength |
| METHYLPREDNISOLONE (UNII: 2 UNII: X4W7Z R7023) | X4W7ZR7023) (M | ETHYLPREDNISOLON | E - | METHYLPREDN | ISOLONE | 2 mg |
| | | | | | | |
| | | | | | | |
| Inactive Ingredients | | | | | | |
| | Ingredie | ent Name | | | S | trength |
| CELLULOSE, MICROCRYSTALLI | NE (UNII: OP1R3 | 2D61U) | | | | |
| HYPROMELLOSE 2910 (15000 | MPA.S) (UNII: 2 | 88VBX44JC) | | | | |
| LACTOSE MONOHYDRATE (UNI | : EWQ57Q8I5X) | | | | | |
| MAGNESIUM STEARATE (UNII: 7 | 0097M6I30) | | | | | |
| SILICON DIOXIDE (UNII: ETJ7Z6) | | | | | | |
| SODIUM STARCH GLYCOLATE | ΓΥΡΕ Α ΡΟΤΑΤΟ |) (UNII: 5856J3G2A2) | | | | |
| | | | | | | |
| Product Characteristics | • | | | | | |
| | | C | | 4 | | |
| | | Score | | | oieces | |
| | VAL | Size | | 7m | | |
| Flavor | | Imprint Code | | L1(|) | |

| Co | ntains | | | | | | |
|-----------------------------------|--|---|---|-----------------|------------------|--------------------------|-----------------------|
| | intanis | | | | | | |
| | | | | | | | |
| Pa | ckaging | | | | | | |
| # | ltem Code | Pa | ckage Description | Marketin Dat | - | Marketir Dat | - |
| | NDC:68180-685- 01 | 100 in 1 BOTT Product | LE; Type 0: Not a Combination | 03/01/2020 | | | |
| | | | | | | | |
| M | arketing | Informat | ion | | | | |
| | Marketing Category | | tion Number or Monograph Citation | | ing Start ate | Marketi Dat | |
| AND | DA | ANDA20909 | 7 | 03/01/2020 | | | |
| | | | | | | | |
| TIC. | thylprednisolo | ne tablet | | | | | |
| | thylprednisolo oduct Infor | | | | | | |
| Pr | | | HUMAN PRESCRIPTION DRUG | ltem Code | (Source) | NDC:681 | .80-686 |
| Pr Pre | oduct Infor | mation | HUMAN PRESCRIPTION DRUG ORAL | ltem Code | (Source) | NDC:681 | .80-686 |
| Pr Pr Ro | oduct Infor oduct Type ute of Admini | mation istration | ORAL | ltem Code | (Source) | NDC:681 | .80-686 |
| Pr Pro Ro | oduct Infor | mation istration | ORAL Moiety | ltem Code | | | |
| Pr Pr Ro Ac | oduct Infor oduct Type ute of Admini tive Ingredi | mation istration ient/Active Ing | ORAL Moiety redient Name | | Basis of S | Strength S | Strengtl |
| Pr Pro Ro Ac | oduct Infor oduct Type ute of Admini tive Ingredi | mation istration ient/Active Ing | ORAL Moiety | | | Strength S | Strengt |
| Pro Ro Ac | roduct Infor oduct Type oute of Admini rtive Ingredi THYLPREDNISO I:X4W7ZR7023) | mation istration ient/Active Ing DLONE (UNII: X4 | ORAL Moiety redient Name | | Basis of S | Strength S | Strengt |
| Pro Ro Ac | oduct Infor oduct Type ute of Admini tive Ingredi | mation istration ient/Active Ing DLONE (UNII: X4 | ORAL Moiety redient Name 4W7Z R7023) (METHYLPREDNISOLO | | Basis of S | Strength S NISOLONE 4 | S trengt mg |
| Pr Ro Ro Ac | roduct Infor oduct Type ute of Admini tive Ingredi THYLPREDNISO I:X4W7ZR7023) | mation istration ient/Active ing DLONE (UNII: X4 | ORAL Moiety redient Name #W7Z R7023) (METHYLPREDNISOLO Ingredient Name | | Basis of S | Strength S NISOLONE 4 | Strengt |
| Pr Pr Ro Ac ME UNI | roduct Infor oduct Type ute of Admini tive Ingredi THYLPREDNISO I:X4W7ZR7023) | mation istration ient/Active ing DLONE (UNII: X4 | ORAL Moiety redient Name 4W7Z R7023) (METHYLPREDNISOLO Ingredient Name IE (UNII: OP1R32D61U) | | Basis of S | Strength S NISOLONE 4 | S trengt mg |
| Pr Pr Ro Ac ME UNI | roduct Infor oduct Type ute of Admini tive Ingredi THYLPREDNISO I:X4W7ZR7023) | mation istration ient/Active ing DLONE (UNII: X4 edients | ORAL Moiety redient Name 4W7Z R7023) (METHYLPREDNISOLO Ingredient Name E (UNII: OP1R32D61U) IPA.S) (UNII: 288VBX44JC) | | Basis of S | Strength S NISOLONE 4 | S trengt mg |

MAGNESIUM STEARATE (UNII: 70097M6I30)

SILICON DIOXIDE (UNII: ETJ7Z6XBU4)

SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)

| Product Characteristics | | | | | | | |
|-------------------------|-------|--------------|----------|--|--|--|--|
| Color | WHITE | Score | 4 pieces | | | | |
| Shape | OVAL | Size | 9mm | | | | |
| Flavor | | Imprint Code | L11 | | | | |
| Contains | | | | | | | |
| | | | | | | | |

| Pa | Packaging | | | | | | | | |
|----|--------------------------------------|--|-------------------------|-----------------------|--|--|--|--|--|
| # | ltem Code | Package Description Marketing Start Date | | Marketing End Date | | | | | |
| | NDC:68180-686- 01 | 100 in 1 BOTTLE; Type 0: Not a Combination Product | 03/01/2020 | | | | | | |
| ~ | NDC:68180-686- 11 | 0-686- 21 in 1 CARTON; Type 0: Not a Combination 03/01/2020 | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| Μ | larketing l | Information | | | | | | | |
| Μ | larketing Marketing Category | I nformation Application Number or Monograph Citation | Marketing Start Date | Marketing End Date | | | | | |
| M | Marketing Category | Application Number or Monograph | - | - | | | | | |

| Product Information | | | | | | | |
|-------------------------|-------------------------|--------------------|---------------|--|--|--|--|
| Product Type | HUMAN PRESCRIPTION DRUG | Item Code (Source) | NDC:68180-687 | | | | |
| Route of Administration | ORAL | | | | | | |
| | | | | | | | |

| Active Ingredient/Active Moiety | | | | | | |
|---|--------------------------|----------|--|--|--|--|
| Ingredient Name | Basis of Strength | Strength | | | | |
| METHYLPREDNISOLONE (UNII: X4W7ZR7023) (METHYLPREDNISOLONE - UNII:X4W7ZR7023) | METHYLPREDNISOLONE | 8 mg | | | | |

| Inactive Ingredients | | | | | |
|--|----------|--|--|--|--|
| Ingredient Name | Strength | | | | |
| CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) | | | | | |
| HYPROMELLOSE 2910 (15000 MPA.S) (UNII: 288VBX44JC) | | | | | |
| LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) | | | | | |
| MAGNESIUM STEARATE (UNII: 70097M6I30) | | | | | |
| SILICON DIOXIDE (UNII: ETJ7Z6XBU4) | | | | | |
| SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) | | | | | |
| | | | | | |

| Product Characterist | cs | | | |
|-----------------------------|-------|--------------|------------------|----------------|
| Color | WHITE | Score | | 2 pieces |
| Shape | OVAL | Size | | 10mm |
| Flavor | | Imprint Code | | L12 |
| Contains | | | | |
| | | | | |
| | | | | |
| Packaging | | | | |
| | | | Maulcation Chart | Mayleating Fod |

| 1 NDC:68180-667 25 in 1 BOTTLE: Type 0: Not a Combination product 03/01/2020 Marketing Information Category Application Number or Monograph Citation Marketing Start Date Marketing Ent Date NDA ANDAZ09097 03/01/2020 03/01/2020 METHYLPREDNISOLONE methylprednisolone tablet Item Code (Source) NDC:68180-688 Product Information Product Type HUMAN PRESCRIPTION DRUG Ingredient Active Molety Item Code (Source) NDC:68180-688 Active Ingredient/Active Molety UNII:X4W/ZR7023) Ingredient Name Basis of Strength Strength ETHYLPREDNISOLONE (UNII: X4W/ZR7023) (METHYLPREDNISOLONE - METHYLPREDNISOLONE 16 mg Inactive Ingredients Ingredient Name Strength CELLULOSE, MICROCRYSTALLINE (UNII: 021R32061U) HYPROMELIOSE 2510 (15000 MA:S) (UNII: 2889X440(:) LACTOSE MONOHYDRATE (UNII: N097Y68ISX) Ingredient Name Strength Strength Strength SILICON DIOXIDE (UNIII: 0097Y68ISX) Ingredient Name Strength Cellulose, MICROCRYSTALLINE (UNII: 021R32061U) Ingredient Name Ingredient Name Cellulose, MICROCRYSTALLINE (UNIII: 021R32061U) Ingredient Name Ingredient Name Stocon MONPORATE (UNIII: N097Y68ISX) Ingredient Name | # Item Code | de Package Description | | | Marketing Start Date | | Marketing End Date | | |
|--|---|------------------------|-----------------|---------------------|-------------------------|-----------------|-----------------------|----------|--|
| Marketing Information Marketing Start Citation Marketing Start Date Marketing Entropy ANDA ANDA209097 03/01/2020 03/01/2020 METHYLPREDNISOLONE methylprednisolone tablet methylprednisolone tablet Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC-68180-688 Route of Administration ORAL Ingredient Name Basis of Strength Strength METHYLPREDNISOLONE (UNII: X4W/ZR7023) Ingredient Name Basis of Strength Strength METHYLPREDNISOLONE (UNII: X4W/ZR7023) Ingredient Name Basis of Strength Strength Inactive Ingredients Ingredient Name Strength Ingredient Iom Inactive Ingredients Ingredient Name Strength Strength CELULOSE, MICROCRYSTALLINE (UNII: 09170820610) HUMEN STRAKE (UNII: 100970810) Iom Iom SULCON DIOXIDE (UNII: ET)726XBU4) Socore 4 pieces Solution Soluto STRACH GLYCOLATE TYPE A POTATO (UNII: 5856)3C2A2) Iom Iom Product Characteristics Iom Iom Iom Color WHITE Score 4 pieces Iom </th <th></th> <th colspan="3"></th> <th>03/01/2020</th> <th></th> <th></th> <th></th> | | | | | 03/01/2020 | | | | |
| Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA209097 03/01/2020 03/01/2020 METHYLPREDNISOLONE Implication Name Implication Name Implication Name Product Information ORAL Imprediation Name Imprediation Name Imprediation Name Active Ingredient/Active Molety Imprediation Name Basis of Strength Strength Imprediation Name METHYLPREDNISOLONE (UNII: X4W/ZR7023) (METHYLPREDNISOLONE - Imprediation Name Strength Strength Active Ingredient/Active Molety Imprediation Name Basis of Strength Strength Strength METHYLPREDNISOLONE (UNII: X4W/ZR7023) (METHYLPREDNISOLONE - METHYLPREDNISOLONE 16 mg Imprediation Name Inactive Ingredients Imprediation Name Strength Strength CELLULOSE, MICROCRYSTALLINE (UNII: 0P1R32D51U) HTHYLPREDNISOLONE (INII: 2889/B362A2) Imprediation Name Strength Solium Strenket (UNII: 1009706130) Imprediation Name Imprediation Name Imprediation Name Imprediation Name Solium Strenket (UNII: 1009706130) Imprediation Name Imprediation Name Imprediation Name Imprediation Name Impred | 33 | TTOULEE | | | | | | | |
| Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA209097 03/01/2020 03/01/2020 METHYLPREDNISOLONE methylprednisolone tablet Imprint Code NDC:68180-688 Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:68180-688 Route of Administration ORAL Impredient Name Basis of Strength Strength Active Ingredient/Active Moiety Impredient Name Basis of Strength Strength Strength METHYLPREDNISOLONE (UNII: X4W7Z R7023) (METHYLPREDNISOLONE - UNII: X4W7Z R7023) METHYLPREDNISOLONE 16 mg Impredient Strength Inactive Ingredients Ingredient Name Strength Strength CELLULOSE, MICROCRYSTALLINE (UNII: 0P1832D61U) HTHYLPREDNISOLONE 16 mg Impredient Start CELLULOSE, MICROCRYSTALLINE (UNII: 20097M6130) SILICON DIOXIDE (UNII: ETTZ 6X8U4) SonDUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856)3G2A2) Strength Product Characteristics Color VHITE Score 4 pieces Shape OVAL Size 10mm Imprint Code L13 Contains | | | | | | | | | |
| Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA209097 03/01/2020 03/01/2020 METHYLPREDNISOLONE Implication Name Implication Name Implication Name Product Information ORAL Imprediation Name Imprediation Name Imprediation Name Active Ingredient/Active Molety Imprediation Name Basis of Strength Strength Imprediation Name METHYLPREDNISOLONE (UNII: X4W/ZR7023) (METHYLPREDNISOLONE - Imprediation Name Strength Strength Active Ingredient/Active Molety Imprediation Name Basis of Strength Strength Strength METHYLPREDNISOLONE (UNII: X4W/ZR7023) (METHYLPREDNISOLONE - METHYLPREDNISOLONE 16 mg Imprediation Name Inactive Ingredients Imprediation Name Strength Strength CELLULOSE, MICROCRYSTALLINE (UNII: 0P1R32D51U) HTHYLPREDNISOLONE (INII: 2889/B362A2) Imprediation Name Strength Solium Strenket (UNII: 1009706130) Imprediation Name Imprediation Name Imprediation Name Imprediation Name Solium Strenket (UNII: 1009706130) Imprediation Name Imprediation Name Imprediation Name Imprediation Name Impred | Marketing I | nformat | ion | | | | | | |
| Category Citation Date Date ANDA ANDA209097 03/01/2020 METHYLPREDNISOLONE methylprednisolone tablet Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:68180-688 Route of Administration ORAL NDC:68180-688 Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength METHYLPREDNISOLONE (UNI: X4W7ZR7023) (METHYLPREDNISOLONE - METHYLPREDNISOLONE is for generative ingredient Name Strength Inactive Ingredients Ingredient Name Strength Strength Inactive Ingredients Ingredient Name Strength Inactive Ingredients Ingredient Name Strength CELLULOSE, MICROCRYSTALLINE (UMI: 0P1832D61U) Ingredient Name Ingredient Name ISULCON DIOXDE (UNI: 170097MGI30) Isucon Dioxone (UNI: 170097MGI30) Isucon Dioxone (UNI: 17097MGI30) SULCON DIOXDE (UNI: 170297MGI30) Ingredient Name Ingredient Name Product Characteristics Ingredient Outil: 10097MGI30) Ingredient Name Color WHITE Score 4 pleces Shape OVAL Size Imgredient Imprint Code L13 Imgredient Prockaging Marketi | - | | | or Monograph | Market | ing Start | Market | ina End | |
| METHYLPREDNISOLONE methylprednisolone tablet Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:68180-688 Route of Administration ORAL Active Ingredient/Active Moiety METHYLPREDNISOLONE (UNII: X4W/ZR7023) (METHYLPREDNISOLONE - METHYLPREDNISOLONE 16 mg METHYLPREDNISOLONE (UNII: X4W/ZR7023) (METHYLPREDNISOLONE - METHYLPREDNISOLONE 16 mg Inactive Ingredients Strength Ingredient Name Strength CELLULOSE, MICROCRYSTALLINE (UNII: 0PIR32D61U) HYPROMELOSE 2910 (15000 MPA.5) (UNII: 289VBX40(C) LACTOSE MONOHYDRATE (UNII: ENQ57Q8ISX) Ingredient S Strength Strength Strength < | | | | | | | | | |
| Product Information HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:68180-688 Route of Administration ORAL Item Code (Source) NDC:68180-688 Active Ingredient/Active Molety Basis of Strength Strength METHYLPREDNISOLONE (UNII: X4W7Z R7023) (METHYLPREDNISOLONE - METHYLPREDNISOLONE 16 mg Inactive Ingredients Ingredient Name Basis of Strength Strength Inactive Ingredients Ingredient Name Strength Inactive Ingredients Strength METHYLPREDNISOLONE 16 mg Inactive Ingredients Strength Strength Cellulose, micRoCRYSTALLINE (UNII: OPIR32D61U) Strength HUMAN STREAMETE (UNII: OPIR32D61U) HyrRoMELLOSE 2910 (15000 MPA.S) (UNII: 28805X4UC) Strength Strength Solicon DioXide (UNII: ETJ7Z 6XBU4) Solicon DioXide (UNII: T0097M6130) Strength Silucon DioXide (UNII: ETJ7Z 6XBU4) Size 10mm Solicon Shape OVAL Size 10mm Flavor Imprint Code L13 Contains Imprint Code L13 | ANDA | ANDA20909 | 7 | | 03/01/2020 |) | | | |
| Product Information HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:68180-688 Route of Administration ORAL Item Code (Source) NDC:68180-688 Active Ingredient/Active Molety Basis of Strength Strength METHYLPREDNISOLONE (UNII: X4W7Z R7023) (METHYLPREDNISOLONE - METHYLPREDNISOLONE 16 mg Inactive Ingredients Ingredient Name Basis of Strength Strength Inactive Ingredients Ingredient Name Strength Inactive Ingredients Strength METHYLPREDNISOLONE 16 mg Inactive Ingredients Strength Strength Cellulose, micRoCRYSTALLINE (UNII: OPIR32D61U) Strength HUMAN STREAMETE (UNII: OPIR32D61U) HyrRoMELLOSE 2910 (15000 MPA.S) (UNII: 28805X4UC) Strength Strength Solicon DioXide (UNII: ETJ7Z 6XBU4) Solicon DioXide (UNII: T0097M6130) Strength Silucon DioXide (UNII: ETJ7Z 6XBU4) Size 10mm Solicon Shape OVAL Size 10mm Flavor Imprint Code L13 Contains Imprint Code L13 | | | | | | | | | |
| Ingredient/Active HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:68180-688 Route of Administration ORAL Item Code (Source) NDC:68180-688 Active Ingredient/Active Molect Basis of Strength Strength METHYLPREDNISOLONE (UNII: X4W7Z R7023) (METHYLPREDNISOLONE - METHYLPREDNISOLONE 16 mg Ingredients METHYLPREDNISOLONE (UNII: X4W7Z R7023) (METHYLPREDNISOLONE - METHYLPREDNISOLONE 16 mg Inactive Ingredients Ingredient Name Strength Cellulose, MICROCRYSTALLINE (UNII: OP1R32D61U) HTYPROMELLOSE 2910 (15000 MPA.S) (UNII: 280/8K44]C) Imactive Ingredients VarCose MONOHYDRATE (UNII: OP1R32D61U) HYPROMELLOSE 2910 (15000 MPA.S) (UNII: 280/8K44]C) Imactive Ingredients Imactive Ingredients VarCose MONOHYDRATE (UNII: C0097M6I30) SILICON DIXIDE (UNII: T072 6X8U4) Imactive Ingredient Name Imactive Ingredient Solium Starch GLYCOLATE TYPE A POTATO (UNII: 5856)3G2A2) Imactive Ingredient Imactive Ingredient Imactive Ingredient Flavor Imarit Code Size Imarit Imarit Imarit Flavor Imarit Code Size Imarit Imarit Imarit Flavor Imarit Code Size Imarit Im | | | | | | | | | |
| Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:68180-688 Route of Administration ORAL Active Ingredient/Active Moiety Basis of Strength Strength METHYLPREDNISOLONE (UNII: X4W/7Z R7023) (METHYLPREDNISOLONE - METHYLPREDNISOLONE 16 mg Ingredient Name Strength Inactive Ingredients Strength Ingredient Name Strength Ingredients Strength Ingredient Name Strength | | | ONE | | | | | | |
| Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:68180-688 Route of Administration ORAL Ingredient/Active Ingredient/Active Molecty Ingredient Name Basis of Strength Strength Active Ingredient/Active Molecty Ingredient Name Basis of Strength Strength METHYLPREDNISOLONE (UNII: X4W7Z R7023) (METHYLPREDNISOLONE I METHYLPREDNISOLONE I 16 mg Inactive Ingredients Strength Cellulose, MICROCRYSTALLINE (UNII: 0P1R32D61U) METHYLPREDNISOLONE I Imgredient Name Cellulose, MICROCRYSTALLINE (UNII: 0P1R32D61U) Hyprometicos 2910 (15000 MPA.S) (UNII: 288V8X4J(C) Strength Cellulose (UNII: 1000 MPA.S) (UNII: 288V8X4J(C) Lactose MonoHypRate (UNII: 0007M610) Silicon Diotoide (UNII: 1772 6X8U4) Sodium starch GLYCOLATE TYPE A POTATO (UNIII: 5856)3G2A2) Product Characteristics Golo WHITE Size 10mm Color WHITE Size Size Size < | methylprednisolor | ne tablet | | | | | | | |
| Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:68180-688 Route of Administration ORAL Ingredient/Active Ingrediant/Active Ingredient/Active | | | | | | | | | |
| ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength METHYLPREDNISOLONE (UNII: X4W7ZR7023) (METHYLPREDNISOLONE - METHYLPREDNISOLONE 16 mg Ingredient Name Basis of Strength Strength Ingredient Name Strength CELLULOSE, MICROCRYSTALLINE (UNII: OPIR32D61U) METHYLPREDNISOLONE - Ingredient Name Strength CELLULOSE, MICROCRYSTALLINE (UNII: OPIR32D61U) — Strength METHYLPREDNISOLONE (UNII: EXQ57Q8ISX) MAGNESIUM STEARATE (UNII: 280/97Q8ISX) — 4 pieces Solum STEARATE (UNII: 20097M6I30) SILICON DIOXIDE (UNII: ETJ726X8U4) — 4 pieces Solum STARCH GLYCOLATE TYPE A POTATO (UNII: 5856/3G2A2) — 4 pieces Shape OVAL Size 100mm Forduct Characteristics — 4 pieces Shape OVAL Size 100mm <th colsp<="" td=""><td>Product Inform</td><td>nation</td><td></td><td></td><td></td><td></td><td></td><td></td></th> | <td>Product Inform</td> <td>nation</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> | Product Inform | nation | | | | | | |
| Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength METHYLPREDNISOLONE (UNII: X4W7ZR7023) (METHYLPREDNISOLONE - METHYLPREDNISOLONE 16 mg Ingredients Ingredients Strength CELLULOSE, MICROCRYSTALLINE (UNII: 0PIR32D61U) HTPROMELLOSE 2910 (15000 MPAR3E) (UNII: 28VBX4JC) Ingredient Name Strength CELLULOSE, MICROCRYSTALLINE (UNII: 0PIR32D61U) HTPROMELLOSE 2910 (15000 MPAR3E) (UNII: 28VBX4JC) Ingredient Name Strength CelLULOSE, MICROCRYSTALLINE (UNII: 0PIR32D61U) HTPROMELLOSE 2910 (15000 MPAR3E) (UNII: 28VBX4JC) Ingredient Name Strength IACTOSE MONOHYDRATE (UNII: 70097M6I30) SILCON DIOXIDE (UNII: ETJ726XBU4) IDGOTO IMETHYLPRE APOTATO (UNII: 5856J3G2A2) IDGOTO Product Characteristics IDGOTO IDGOTO IDGOTO Imprint Code IDGOTO IDGOTO Frackaging IDGOTO IDGOTO IDGOTO IDGOTO | Product Type | | HUMAN PRESC | CRIPTION DRUG | Item Code | e (Source) | NDC:68 | 180-688 | |
| Ingredient Name Basis of Strength Strength METHYLPREDNISOLONE (UNII: X4W7ZR7023) (METHYLPREDNISOLONE - METHYLPREDNISOLONE (UNII: X4W7ZR7023) (METHYLPREDNISOLONE - In active Ingredients Strength Ingredient Name Strength Ingredient Name Strength Ingredient Name Strength CELLULOSE, MICROCRYSTALLINE (UNII: 0P1R32D61U) H HYPROMELLOSE 2910 (15000 MPA.S) (UNII: 288VBX44JC) Strength Ingredient Name Strength CELLULOSE, MICROCRYSTALLINE (UNII: 20070815X) METHYLPRE NTO097M6130) SILICON DIOXIDE (UNII: EVQ57Q815X) METHYLPRE A POTATO (UNII: 5856J3G2A2) VOLUC Characteristics Solum Starch GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) UNII: 5856J3G2A2) VAL Size 10mm Ingredient Code 113 VAL Size Marketing End NDC Kealing Marketing Start Marketing End | Route of Adminis | tration | ORAL | | | | | | |
| Ingredient Name Basis of Strength Strength METHYLPREDNISOLONE (UNII: X4W7Z R7023) (METHYLPREDNISOLONE - METHYLPREDNISOLONE 16 mg Inactive Ingredients Strength Ingredient Name Strength Ingredients Strength Ingredient Name Strength CELLULOSE, MICROCRYSTALLINE (UNII: 001R32D61U) H HYPROMELLOSE 2910 (15000 MPA.S) (UNII: 288VBX4JC) LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) METHYLPRE A POTATO (UNII: 5856J3G2A2) Strength OVAL Score 4 pieces Solum Starch GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) LI3 Product Characteristics Color WHITE Score 4 pieces Shape OVAL Size LI3 Product Characteristics Lage Strength Imprint Code LI3 Contains Solum BROTHE : Top 0: No | | | | | | | | | |
| Ingredient Name Basis of Strength Strength METHYLPREDNISOLONE (UNII: X4W7Z R7023) (METHYLPREDNISOLONE - METHYLPREDNISOLONE 16 mg Ingredients Strength Ingredients Strength Ingredients Strength Ingredient Name Strength CELLULOSE, MICROCRYSTALLINE (UNII: 0P1R32D61U) H HYPROMELLOSE 2910 (15000 MPA.S) (UNII: 28VBX4JC) Strength LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) METHYLPRE A POTATO (UNII: 5856J3G2A2) METHYLPREAPOTATO (UNII: 5856J3G2A2) Strength Product Characteristics Color WHITE Score 4 pieces Shape OVAL Size 10mm Falavor Imprint Code L13 Packaging Marketing Start Marketing Start Marketing Start Marketing Start | | | | | | | | | |
| METHYLPREDNISOLONE (UNII: X4W7ZR7023) (METHYLPREDNISOLONE - UNII: X4W7ZR7023) METHYLPREDNISOLONE I I6 mg Ingredients Ingredient Name Strength CelLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) H Strength CelLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) H Strength AGNOROHYDRATE (UNII: OP1R32D61U) H Strength AGNOROHYDRATE (UNII: OP1R32D61U) H Strength METHYLPREDNISOLONE - UNII: 288VBX44JC) L Colspan="2">Strength Strength Strength S | Active Ingredie | ent/Active | Moiety | | | | | | |
| Inactive Ingredients Ingredient Name Strength CELLULOSE, MICROCRYSTALLINE (UNII: OPIR32D61U) HYPROMELLOSE 2910 (15000 MPA.S) (UNII: 288VBX44JC) Image: Comparison of the comparison of t | | Ing | redient Nam | ne | | Basis of | Strength | Strength | |
| Ingredients Ingredient Name Strength CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) Strength HYPROMELLOSE 2910 (15000 MPA.S) (UNII: 288VBX44JC) LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) SILICON DIOXIDE (UNII: ETJ7Z 6XBU4) Solum STEARATE (UNII: 70097M6I30) SILICON DIOXIDE (UNII: ETJ7Z 6XBU4) Solum STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) Imprint Cole Product Characteristics Color WHITE Score 4 piecs Shape OVAL Size 10mm Imprint Code 1011 Fackaging | | LONE (UNII: X4 | 4W7ZR7023) (M | ETHYLPREDNISOLO | NE - | METHYLPRE | DNISOLONE | 16 mg | |
| Ingredient Name Strength CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D610) Strength HYPROMELLOSE 2910 (15000 MPA.S) (UNII: 288VBX44JC) LACTOSE MONOHYDRATE (UNII: FWQ57Q8ISX) MAGNESIUM STEARATE (UNII: 70097M6I30) SILICON DIOXIDE (UNII: ETJ7Z6XBU4) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) Y Product Characteristics Stape OVAL OVAL Size Packaging Marketing Start Dis 1 BOTHE: Type 0: Net 2 Combination | | | | | | | | | |
| Ingredient Name Strength CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D610) Strength HYPROMELLOSE 2910 (15000 MPA.S) (UNII: 288VBX44JC) LACTOSE MONOHYDRATE (UNII: FWQ57Q8ISX) MAGNESIUM STEARATE (UNII: 70097M6I30) SILICON DIOXIDE (UNII: ETJ7Z6XBU4) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) Y Product Characteristics Stape OVAL OVAL Size Packaging Marketing Start Dis 1 BOTHE: Type 0: Net 2 Combination | | | | | | | | | |
| CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) I HYPROMELLOSE 2910 (15000 MPA.S) (UNII: 288VBX44JC) I LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) I MAGNESIUM STEARATE (UNII: 70097M6130) I SILICON DIOXIDE (UNII: ETJ7Z 6XBU4) I SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) I Product Characteristics I Color WHITE Score 4 pieces Shape OVAL Size 10mm Flavor Imprint Code L13 Contains I Marketing Start Date Marketing End Date | Inactive Ingred | lients | | | | | | | |
| HYPROMELLOSE 2910 (1500 MPA.S) (UNII: 283VBX44JC) Image: constant to the state of the st | | | Ingredie | ent Name | | | St | rength | |
| LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) Image: Support of the sup | CELLULOSE, MICRO | OCRYSTALLIN | IE (UNII: OP1R3 | 2D61U) | | | | | |
| MAGNESIUM STEARATE (UNII: 70097M6130) Image: Solution of the state of the st | | | | 38VBX44JC) | | | | | |
| SILICON DIOXIDE (UNII: ETJ7Z6X8U4) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856j3G2A2) Product Characteristics Color MHITE Score 4 pieces Shape 0VAL Size 10mm Flavor 0VAL Size 10mm Imprint Code L13 Contains Packaging # Item Code Package Description Marketing Start Date Marketing Enc | | | | | | | | | |
| SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) Product Characteristics Color WHITE Score 4 pieces Shape OVAL Size 10mm Flavor Imprint Code L13 Contains Imprint Code Marketing Start Package Description Marketing Start Marketing End NDC:68180.688 50 in 1 BOITLE: Type 0: Not a Combination Combination | | - | · · | | | | | | |
| Product Characteristics Color WHITE Score 4 pieces Shape OVAL Size 10mm Flavor Imprint Code L13 Contains Imprint Code Marketing Start Package Description Marketing Start Marketing End Date | | | |) (UNII: 585613G2A2 | 2) | | | | |
| VHITE Score 4 pieces Shape OVAL Size 10mm Flavor Imprint Code L13 Contains Imprint Code Score | | | | | | | | | |
| VHITE Score 4 pieces Shape OVAL Size 10mm Flavor Imprint Code L13 Contains Intervent Value | | | | | | | | | |
| Shape OVAL Size 10mm Flavor Imprint Code L13 contains Imprint Code L13 Flavor Imprint Code Imprint Code Flavor Imprint Code Imprint Code Imprint Code Imprint Code Imprint Code < | Product Chara | cteristics | | | | | | | |
| Flavor Imprint Code L13 Contains Imprint Code L13 Packaging Item Code Package Description Marketing Start Marketing End Date NDC:68180 688 50 in 1 BOTTLE: Type 0: Not a Combination | Color | olor WHITE Score | | | | | 4 pieces | | |
| Contains Addition Packaging Marketing Start Marketing End Date # Item Code Package Description Marketing Start Date Marketing End Date NDC:68180.688 50 in 1 BOTTLE: Type 0: Not a Combination Combination Combination | Shape | OV | | | | 10mm | | | |
| Packaging # Item Code Package Description Marketing Start Date Marketing End Date NDC:68180_688_50 in 1_ROTTLE: Type 0: Not a Combination Date Date | | | | Imprint Code | | | L13 | | |
| # Item Code Package Description Marketing Start Date Marketing End Date NDC:68180.688 50 in 1 ROTTLE: Type 0: Not a Combination | Contains | | | | | | | | |
| # Item Code Package Description Marketing Start Date Marketing End Date NDC:68180.688 50 in 1 ROTTLE: Type 0: Not a Combination | | | | | | | | | |
| # Item Code Package Description Marketing Start Date Marketing End Date NDC:68180.688 50 in 1 ROTTLE: Type 0: Not a Combination | | | | | | | | | |
| # Item Code Package Description Date Date | Dackaging | | | | | | | | |
| NDC:68180-688- 50 in 1 BOTTLE; Type 0: Not a Combination | | | | | Markatin | a Start | Markati | na End | |
| 1 08 Product 03/01/2020 | | Pa | ckage Desc | ription | | - | | - | |

| Marketing Ir | nformat | ion | | | |
|-------------------------------------|---|----------------|----------------------------|-------------------------|-----------------------|
| Marketing Category | Application Number or Monograph Citation | | Marketing Start Date | Marketing End | |
| ANDA | ANDA20909 | 0 | | 03/01/2020 | Dutt |
| | | | | | |
| METHYLPRE | ONISOL | ONE | | | |
| methylprednisolon | e tablet | | | | |
| Product Inform | ation | | | | |
| Product Type | | HUMAN PRES | CRIPTION DRUG | Item Code (Source |) NDC:68180-689 |
| Route of Administ | tration | ORAL | | | |
| | | | | | |
| Active Ingredie | | - | | | |
| | | redient Nai | | | f Strength Strengt |
| METHYLPREDNISOL UNII:X4W7ZR7023) | ONE (UNII: X | 4W7ZR7023) (N | METHYLPREDNISOLO | NE - METHYLPR | EDNISOLONE 32 mg |
| Inactive Ingred | ients | | | | |
| | | - | ent Name | | Strength |
| CELLULOSE, MICRO | | | | | |
| HYPROMELLOSE 293 | | | 288VBX44JC) | | |
| MAGNESIUM STEAR | | | | | |
| SILICON DIOXIDE (U | | | | | |
| SODIUM STARCH GL | - | | O (UNII: 5856J3G2A2 | 2) | |
| | | | | | |
| Product Charac | teristics | | | | |
| Color | | IITE | Score | | 2 pieces |
| Shape | 0\ | /AL | Size | | 13mm |
| Flavor | | | Imprint Code | | L14 |
| Contains | | | | | |
| Packaging | | | | | |
| # Item Code | Pa | ckage Deso | cription | Marketing Start Date | Marketing End Date |
| | 25 in 1 BOTTI Product | E; Type 0: Not | t a Combination | 03/01/2020 | Date |
| 55 F | Jude | | | | |
| | | | | | |

| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
|-----------------------|---|-------------------------|-----------------------|
| ANDA | ANDA209097 | 03/01/2020 | |
| | | | |

Labeler - Lupin Pharmaceuticals, Inc. (089153071)

Revised: 12/2021

Lupin Pharmaceuticals, Inc.